Overview

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

Status:
Not yet recruiting

Trial end date:
2024-06-15

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the efficacy, safety, tolerability, and immunogenicity of ADL-018 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment

Phase:

Phase 3

Details

Lead Sponsor:

Kashiv BioSciences, LLC

Treatments:

Omalizumab